The FDA has accepted a supplemental Biologics License Application (sBLA) for Botox Cosmetic to treat masseter muscle prominence, advancing AbbVie's effort to expand the toxin's approved indications beyond the current glabellar, forehead, and crow's feet labels.
Regulatory
FDA Accepts sBLA for Botox in Masseter Prominence
AbbVie advances jawline indication; regulatory path clears for new patient population.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Masseter Botox approval could unlock premium-priced jawline market for practices.
Masseter treatment is already performed off-label by many practices, but FDA approval would formalize the indication, enable manufacturer-backed training and marketing, and likely drive patient demand through direct-to-consumer channels. For practice owners, this represents a revenue opportunity—masseter Botox commands premium pricing (often $15–25 per unit vs. $12–18 for standard facial units) and appeals to patients seeking jawline definition without surgery. Approval timing remains uncertain, but the sBLA acceptance suggests a 2026–2027 launch window is plausible.
Source: original report ↗
Frequently asked questions
How much can I charge for Botox masseter treatment?
Masseter Botox typically commands $15–25 per unit, compared to $12–18 for standard facial units, making it a premium offering. Pricing varies by geography, practice positioning, and local competition, but the higher unit cost reflects both the larger muscle mass and growing patient demand for non-surgical jawline definition.
When will Botox be approved for masseter treatment?
The FDA has accepted AbbVie's supplemental Biologics License Application (sBLA) for masseter indication, with a plausible launch window of 2026–2027. Exact approval timing remains uncertain, but sBLA acceptance signals the regulatory path is clear.
Is masseter Botox currently legal to perform?
Yes, masseter Botox is legal to perform off-label today, and many practices already offer it. However, FDA approval will formalize the indication, enabling manufacturer-backed training and marketing, which will likely increase patient awareness and demand.
What are the benefits of FDA approval for masseter Botox?
FDA approval will allow AbbVie to provide official training, marketing support, and direct-to-consumer promotion, driving patient demand. For practices, this means access to manufacturer resources, clearer clinical guidance, and a larger patient pool seeking jawline definition without surgery.
How is masseter Botox different from other facial Botox treatments?
Masseter treatment targets the jaw muscle to reduce prominence and create jawline definition, versus glabellar, forehead, and crow's feet treatments that address expression lines. The masseter muscle is larger, requiring more units and justifying the premium pricing of $15–25 per unit.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.